8-KEarnings & ResultsExhibits & Filings

AbbVie Inc. 8-K Report, Financial Results (Jan 6, 2025)

Filed January 6, 2025For Securities:ABBV

Summary

AbbVie Inc. (ABBV) has filed a Current Report (8-K) on January 6, 2025, providing a crucial update on its financial performance, specifically concerning the fourth quarter of 2024. The company anticipates significant acquired IPR&D (In-Process Research & Development) and milestones expenses, estimated at $1.6 billion on a pre-tax basis. This expense is expected to negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.88 each. Investors should note that these are preliminary estimates and the final results may differ. The company has also revised its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.02 - $10.06, incorporating this substantial fourth-quarter expense. The updated fourth-quarter 2024 adjusted diluted earnings per share guidance is now projected to be between $2.06 - $2.10. This filing highlights the financial impact of strategic acquisitions and licensing agreements, which, while strategically important for future growth, introduce a degree of variability and expense that was not previously forecast beyond the third quarter of 2024.

Key Highlights

  • 1AbbVie expects significant acquired IPR&D and milestones expenses of $1.6 billion (pre-tax) in Q4 2024.
  • 2These expenses are projected to reduce both GAAP and adjusted non-GAAP diluted EPS by $0.88 for Q4 2024.
  • 3Full-year 2024 adjusted diluted EPS guidance is revised to $10.02 - $10.06, reflecting the Q4 expense.
  • 4Q4 2024 adjusted diluted EPS guidance is now $2.06 - $2.10.
  • 5The company notes these are preliminary estimates and final results may vary.
  • 6The acquired IPR&D and milestones expense was not previously forecast beyond Q3 2024.

Frequently Asked Questions

The primary reason for the updated financial guidance is the recognition of significant acquired In-Process Research & Development (IPR&D) and milestones expenses totaling an estimated $1.6 billion on a pre-tax basis during the fourth quarter of 2024.

These acquired IPR&D and milestones expenses are expected to have an unfavorable impact of $0.88 on both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share for the fourth quarter of 2024.

AbbVie's full-year 2024 adjusted diluted earnings per share guidance, including the impact of the fourth quarter acquired IPR&D and milestones expense, is now in the range of $10.02 to $10.06.

No, the reported figures for the quarter ended December 31, 2024, are preliminary estimates. AbbVie states that the results have not been finalized and are subject to financial statement closing procedures, meaning final results could differ.